In June, the FDA gave the green light to the controversial Alzheimer’s drug Aduhelm from Biogen, although an advisory committee had previously spoken out against it.
(Photo: AP)
Bangalore The Samsung Group rejects a newspaper report that the South Korean conglomerate is considering a multi-billion dollar takeover of the US biotech company Biogen. The report of the newspaper “Korea Economic Daily” was “not true”, wrote the biotech unit Samsung BioLogics in an approval application on Wednesday without giving further details.
The paper had previously reported on the possible deal, citing banking circles, which would have valued Biogen in a transaction with around 42 billion dollars. Biogen said it did not comment on market rumors or speculation. The company’s share closed on Wednesday up 9.5 percent.
In June, the FDA gave the green light to the controversial Alzheimer’s drug Aduhelm from Biogen, although an advisory committee had previously spoken out against it. The Alzheimer’s drug business has been sluggish since then.
The Samsung Group announced in August that it would invest almost $ 206 billion over the next three years. The money is to flow into the areas of biopharmaceuticals, artificial intelligence, semiconductors and the robot industry. According to the information at the time, the investments should help to strengthen the global position in key industries such as the chip sector and to boost growth in the post-corona period.
Top jobs of the day
Find the best jobs now and
be notified by email.
More: Doubts about effectiveness and criticism of the high price weigh on the launch of Biogen’s Alzheimer’s drug